Vericiguat (Verquvo)


 CADTH recommends that Verquvo be reimbursed by public drug plans for the treatment of chronic heart failure (HF) as an adjunct to standard care therapy if certain conditions are met.
 should only covered treat adult patients: whose is unable pump enough blood keep up with body’s needs because too weak (i.e., HF reduced ejection fraction); who considered symptomatic (e.g., slight limitation in physical activity, defined New York Heart Association [NYHA] functional classification class II; a marked NYHA III; or symptoms even at rest, IV); and had recent hospitalization needed receive IV medicines.
 price reduced.